The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial

Background: Infections caused by multidrug-resistant (MDR) pathogen have caused a resurgence of interest in colistin. To date, information about the effectiveness of Aerosolized Colistin (AS) is very limited in the treatment of Ventilator-Associated Pneumonia (VAP). The aim of this study is to evalu...

Full description

Bibliographic Details
Main Authors: Faezeh Feizabadi, Seyed Mohammad Reza Hashemian, Zahra Mirshafiei, Farzaneh Dastan
Format: Article
Language:English
Published: Research Center for Rational Use of Drugs (RCRUD) 2021-09-01
Series:Journal of Pharmaceutical Care
Subjects:
Online Access:https://jpc.tums.ac.ir/index.php/jpc/article/view/431
_version_ 1818390512234659840
author Faezeh Feizabadi
Seyed Mohammad Reza Hashemian
Zahra Mirshafiei
Farzaneh Dastan
author_facet Faezeh Feizabadi
Seyed Mohammad Reza Hashemian
Zahra Mirshafiei
Farzaneh Dastan
author_sort Faezeh Feizabadi
collection DOAJ
description Background: Infections caused by multidrug-resistant (MDR) pathogen have caused a resurgence of interest in colistin. To date, information about the effectiveness of Aerosolized Colistin (AS) is very limited in the treatment of Ventilator-Associated Pneumonia (VAP). The aim of this study is to evaluate the efficacy and safety of AS in conjunction with intravenous (IV) colistin in patients with VAP, caused by MDR Gram-Negative Bacteria (GNB).Methods: This parallel randomized clinical trial was conducted on patients with VAP in the Intensive Care Unit (ICU) ward. 27 patients allocated to the intervention or the control group. Patients in the intervention group received IV Colistin based on glomerular filtration rate along with aerosolized Colistin, 2 million units three times a day. In the control group, only IV Colistin was administered. For all patients, Procalcitonin (PCT), sputum culture, and Clinical Pulmonary Infection Score (CPIS) were evaluated and compared as outcome measures at the specified period of time.Results: Negative sputum culture was achieved in 9 (80%) out of 11 patients in the AS-IV Colistin group after seven days of therapy versus 9 (56.25%) out of 16 in the control group (P= 0.01). PCT and CPIS scores were not significantly different between two groups (P=0.21, P= 0.62). Furthermore, nephrotoxicity and neurotoxicity were not seen.Conclusion: AS Colistin lead to earlier negative sputum culture without increasing risk of nephrotoxicity and neurotoxicity, and could potentially be a beneficial adjunctive approach in the management of MDR-VAP.
first_indexed 2024-12-14T04:58:48Z
format Article
id doaj.art-69853411c56e483497826f2b725562c5
institution Directory Open Access Journal
issn 2322-4630
2322-4509
language English
last_indexed 2024-12-14T04:58:48Z
publishDate 2021-09-01
publisher Research Center for Rational Use of Drugs (RCRUD)
record_format Article
series Journal of Pharmaceutical Care
spelling doaj.art-69853411c56e483497826f2b725562c52022-12-21T23:16:16ZengResearch Center for Rational Use of Drugs (RCRUD)Journal of Pharmaceutical Care2322-46302322-45092021-09-019310.18502/jpc.v9i3.7368The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical TrialFaezeh Feizabadi0Seyed Mohammad Reza Hashemian1Zahra Mirshafiei2Farzaneh Dastan3Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.Pharmaceutical Care Department, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran AND Pharmaceutical Care Department, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.Background: Infections caused by multidrug-resistant (MDR) pathogen have caused a resurgence of interest in colistin. To date, information about the effectiveness of Aerosolized Colistin (AS) is very limited in the treatment of Ventilator-Associated Pneumonia (VAP). The aim of this study is to evaluate the efficacy and safety of AS in conjunction with intravenous (IV) colistin in patients with VAP, caused by MDR Gram-Negative Bacteria (GNB).Methods: This parallel randomized clinical trial was conducted on patients with VAP in the Intensive Care Unit (ICU) ward. 27 patients allocated to the intervention or the control group. Patients in the intervention group received IV Colistin based on glomerular filtration rate along with aerosolized Colistin, 2 million units three times a day. In the control group, only IV Colistin was administered. For all patients, Procalcitonin (PCT), sputum culture, and Clinical Pulmonary Infection Score (CPIS) were evaluated and compared as outcome measures at the specified period of time.Results: Negative sputum culture was achieved in 9 (80%) out of 11 patients in the AS-IV Colistin group after seven days of therapy versus 9 (56.25%) out of 16 in the control group (P= 0.01). PCT and CPIS scores were not significantly different between two groups (P=0.21, P= 0.62). Furthermore, nephrotoxicity and neurotoxicity were not seen.Conclusion: AS Colistin lead to earlier negative sputum culture without increasing risk of nephrotoxicity and neurotoxicity, and could potentially be a beneficial adjunctive approach in the management of MDR-VAP.https://jpc.tums.ac.ir/index.php/jpc/article/view/431Colistin; Multiple Drug Resistance; Ventilator-Associated Pneumonia
spellingShingle Faezeh Feizabadi
Seyed Mohammad Reza Hashemian
Zahra Mirshafiei
Farzaneh Dastan
The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial
Journal of Pharmaceutical Care
Colistin; Multiple Drug Resistance; Ventilator-Associated Pneumonia
title The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial
title_full The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial
title_fullStr The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial
title_full_unstemmed The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial
title_short The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial
title_sort potential role of aerosolized colistin in the ventilator associated pneumonia management caused by multidrug resistant gram negative bacteria a randomized clinical trial
topic Colistin; Multiple Drug Resistance; Ventilator-Associated Pneumonia
url https://jpc.tums.ac.ir/index.php/jpc/article/view/431
work_keys_str_mv AT faezehfeizabadi thepotentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial
AT seyedmohammadrezahashemian thepotentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial
AT zahramirshafiei thepotentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial
AT farzanehdastan thepotentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial
AT faezehfeizabadi potentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial
AT seyedmohammadrezahashemian potentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial
AT zahramirshafiei potentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial
AT farzanehdastan potentialroleofaerosolizedcolistinintheventilatorassociatedpneumoniamanagementcausedbymultidrugresistantgramnegativebacteriaarandomizedclinicaltrial